Alterity Therapeutics (ATHE) Gross Profit (2009 - 2010)

Alterity Therapeutics' (ATHE) quarterly Gross Profit came in at -$4.3 million in Q2 2010, up 24.02% year-on-year from -$3.5 million in Q2 2009, and up 24.02% quarter-over-quarter from -$5.7 million in Q2 2009.

Alterity Therapeutics (ATHE) Gross Profit (2009 - 2010) Analysis & Trends

Alterity Therapeutics' Gross Profit history runs 2 years deep, the most recent figure standing at -$4.3 million for Q2 2010.

  • On a quarterly basis, Gross Profit rose 24.02% year-over-year to -$4.3 million in Q2 2010; TTM through Jun 2010 was -$4.3 million, a 24.02% increase from a year earlier, with the FY2012 full-year figure at $192659.8, up 16.22% from the prior year.
  • Gross Profit grew to -$4.3 million in Q2 2010 per ATHE's latest filing, from -$5.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at -$4.3 million in Q2 2010 and bottomed at -$5.7 million in Q2 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Alterity Therapeutics 29.68 Bn 29.68 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2010 -4.34 Mn
Jun 30, 2010 -4.34 Mn
Jun 30, 2009 -5.71 Mn
Jun 30, 2009 -5.71 Mn